日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study

伊扎隆单抗布伦吉特康治疗局部晚期或转移性非小细胞肺癌(伴有除经典 EGFR 突变以外的可靶向基因组改变):一项 Ib 期研究

Zhou, Huaqiang; Zhao, Hongyun; Hou, Xue; Wang, Yongsheng; He, Zhiyong; Li, Yongsheng; Ma, Yuxiang; Zhao, Yuanyuan; Huang, Yan; Chen, Likun; Xiao, Sa; Zhu, Hai; Zhu, Yi; Fang, Wenfeng; Zhang, Li; Yang, Yunpeng

First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial

一线替雷利珠单抗联合化疗治疗复发或转移性鼻咽癌:RATIONALE-309 III期随机临床试验的三年随访

Yang, Yunpeng; Yen, Chia-Jui; Pan, Jianji; Wang, Hui; Qu, Shenhong; Chen, Nianyong; Chen, Xiaozhong; Sun, Yan; He, Xiaohui; Hu, Chaosu; Lin, Lizhu; Wu, Yanjie; Yuan, Shuai; Chen, Chenqi; Xu, Xingxing; Ma, Xiaopeng; Leaw, Shiangjiin; Zhang, Li; Fang, Wenfeng

Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial

卡瑞利珠单抗联合化疗治疗复发或转移性鼻咽癌的五年疗效:CAPTAIN-1st随机临床试验的二次分析

Huang, Yan; Sun, Dongchen; Zhou, Huaqiang; Zhou, Ting; Qu, Song; Li, Jingao; Hu, Chaosu; Xu, Mingjun; Li, Weidong; Shen, Liangfang; Wu, Hui; Lang, Jinyi; Hu, Guangyuan; Luo, Zhanxiong; Fu, Zhichao; Qu, Shenhong; Feng, Weineng; Chen, Xiaozhong; Lin, Shaojun; Xie, Bo; Li, Xiaojiang; Sun, Yan; Lin, Zhixiong; Lin, Qin; Lei, Feng; Long, Jianting; Hong, Jinsheng; Huang, Xiaoming; Zeng, Lingzhi; Wang, Peiguo; He, Xiaohui; Zhao, Shen; Chen, Gang; Zhang, Yaxiong; Zhao, Yuanyuan; Fang, Wenfeng; Huang, Chuanpei; Li, Xiaotong; Hong, Shaodong; Zhang, Li; Yang, Yunpeng

Crotonylation driving Streptococcus pneumoniae adaption and virulence

巴豆酰化驱动肺炎链球菌的适应性和毒力

Li, Nan; Zhuang, Jianpeng; Wu, Jiayi; Xue, Zhuoti; Xu, Jiayi; Fang, Zuye; Zheng, Yundan; Liu, Yun; Yang, Yunpeng; Ye, Xinyu; He, Qing-Yu; Sun, Xuesong

Safety and Efficacy of Lucitanib Plus Toripalimab in Advanced Solid Tumors Refractory to Standard Therapies: An Open-Label, Multicenter, Phase II Study

Lucitanib联合Toripalimab治疗对标准疗法耐药的晚期实体瘤的安全性和有效性:一项开放标签、多中心、II期研究

Zhou, Ting; Sun, Haishuang; Chen, Gang; Zhang, Guoping; Wu, Jinsheng; Qu, Shenhong; Han, Yaqian; Hu, Desheng; Ling, Yang; Zheng, Yulong; Liu, Jian; Lin, Lizhu; Li, Yongsheng; Pan, Jianji; Liu, Yanyan; Wang, Cuiying; Fu, Guohong; Feng, Jian; Shi, Jianhua; Cai, Huiming; Li, Meng; Li, Fugen; Wang, Yinbin; Zhang, Li; Yang, Yunpeng

Anti-LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial

抗LAG-3抗体LBL-007联合替雷利珠单抗和化疗作为晚期鼻咽癌一线治疗:一项多中心II期试验

Sun, Dongchen; Chen, Gang; Chen, Yu; Qu, Song; Liu, Lei; Yang, Kunyu; Li, Jingao; Chen, Lisha; Huang, Xiaoming; Zhu, Haisheng; Tang, Wenjun; Wang, Rensheng; Han, Yaqian; Hu, Desheng; Gao, Jin; Chen, Xiaozhong; Xiong, Hailin; Chen, Wu; Fan, Bin; Cai, Shengli; Kang, Xiaoqiang; Zhang, Li; Yang, Yunpeng

Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R

EGFR突变型肺腺癌中,外显子19缺失突变和外显子21 L858R突变之间存在多种基因组和转录组异质性。

Yang, Yuwen; Qiao, Sitan; Sun, Dongchen; Zhang, Zhonghan; Zhao, Yuanyuan; Zhan, Jianhua; Huang, Yan; Zhao, Hongyun; Yang, Yunpeng; Wu, Kui; Zhou, Xinlan; Zhang, Lanjun; Long, Hao; Yang, Haoxian; Wang, Junye; Wang, Xin; Wen, Zhesheng; Zhang, Lin; Zhang, Li; Fang, Wenfeng; Zhao, Xin; Zhang, Yaxiong

Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors.

采用冷冻消融术联合肿瘤内 TLR9 激动剂和双重检查点抑制剂来激发抗肝癌免疫反应。

Yang Yunpeng, Mandt Tyler, Mittelstein David, Das Manasi, Wu Panyisha, Ghani Mansur A, Illindala Ritvik, Steinmetz Nicole F, Burgoyne Adam M, Berman Zachary, Webster Nicholas, Newton Isabel G

Genomic biomarkers of immunotherapy plus chemotherapy in patients with advanced NSCLC: Insights from the phase 3 ORIENT-11 study

晚期非小细胞肺癌患者免疫疗法联合化疗的基因组生物标志物:来自 3 期 ORIENT-11 研究的启示

Liao, Jun; Huang, Jie; Chen, Xueyuan; Hong, Shaodong; Chen, Gang; Zhang, Yaxiong; Zhou, Ting; Zhuang, Weitao; Pang, Lanlan; Yang, Yunpeng; Zhang, Li; Fang, Wenfeng

Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial

新辅助纳武利尤单抗联合化疗及同步放化疗(CA209-7AL)后,对不可切除的III期非小细胞肺癌患者进行巩固性纳武利尤单抗治疗与观察的疗效比较:一项随机临床试验

Qiu, Bo; Zhao, Yuanyuan; He, Wenzhuo; Zeng, Weijin; Zhang, Hongmei; Feng, Weineng; Jia, Jun; Wang, Daodu; Wang, Daquan; Liu, Fangjie; Liu, Songran; Yin, Shaohan; Xie, Chuanmiao; Zhou, Rui; Hu, Yi; Liu, Qianwen; Guo, Jinyu; Guo, Suping; Wu, Yingjia; Luo, Qiaoting; Li, Jibin; Yang, Yunpeng; Xia, Liangping; Zhang, Li; Liu, Hui